Key result
Anthracycline-induced cardiomyopathy is a severe complication of cancer therapy, making early echocardiographic screening and prevention with cardioprotective agents like dexrazoxane crucial.
This review summarizes the pathophysiology, risk factors, diagnosis, and cardioprotective strategies for anthracycline-induced cardiomyopathy, emphasizing the role of dexrazoxane and early echocardiographic monitoring.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kraus et al. (2008) conducted a review in Anthracycline-induced cardiomyopathy. Cardioprotective agents (e.g., dexrazoxane, ACE inhibitors, beta-blockers) was evaluated. Anthracycline-induced cardiomyopathy is a severe complication of cancer therapy, making early echocardiographic screening and prevention with cardioprotective agents like dexrazoxane crucial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: